L & S Advisors’s AstraZeneca AZN Stock Holding History

L & S Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.62M	Buy	24,346 +733	+3%	+$138K	0.48%	78
2026 Q1	$4.66M	Sell	23,613 -18,733	-44%	-$3.61M	0.59%	54
2025 Q4	$7.79M	Buy	+42,346	New	+$7.43M	0.72%	35
2016 Q4	–	Sell	-49,814	Closed	-$3.27M	–	165
2016 Q3	$3.27M	Buy	+49,814	New	+$3.26M	0.9%	43
2015 Q1	–	Sell	-19,742	Closed	-$1.39M	–	89
2014 Q4	$1.39M	Buy	19,742 +14,379	+268%	+$1.03M	0.43%	57
2014 Q3	$383K	Sell	5,363 -31,159	-85%	-$2.28M	0.19%	45
2014 Q2	$2.71M	Buy	36,522 +27,970	+327%	+$2.02M	1.08%	33
2014 Q1	$555K	Buy	+8,552	New	+$552K	0.3%	52

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

L & S Advisors's AZN Position: Q2 2026 in Review

L & S Advisors increased its AstraZeneca (AZN) stake by 3.1% in Q2 2026, buying an estimated $138K and bringing the position to 24,346 shares worth $4.62M. The position accounts for 0.48% of the portfolio, ranked #78.

L & S Advisors first reported a position in AZN in Q1 2014 and has held it in 8 quarters since. The position peaked at $7.79M in Q4 2025. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

L & S Advisors held 24,346 shares of AstraZeneca worth $4.62M as of Q2 2026.
L & S Advisors bought 733 AstraZeneca shares in Q2 2026, an estimated $138K.
AstraZeneca made up 0.48% of L & S Advisors's portfolio in Q2 2026, its #78 holding.
L & S Advisors first reported a position in AstraZeneca in Q1 2014 and has held it in 8 quarters since.
L & S Advisors's AstraZeneca position peaked at $7.79M in Q4 2025.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on L & S Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.